{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:35:20Z","timestamp":1793306120957,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022894","name":"All India Institute of Medical Sciences, Jodhpur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022894","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10787-025-01995-5","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:46:53Z","timestamp":1759654013000},"page":"6983-6991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-inflammatory potential of telmisartan compared to other antihypertensives: secondary outcomes from a randomized trial"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5084-336X","authenticated-orcid":false,"given":"Simi Bridjit","family":"Gomaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6725","authenticated-orcid":false,"given":"Jaykaran","family":"Charan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3129-6352","authenticated-orcid":false,"given":"Amal","family":"Mohandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9555-753X","authenticated-orcid":false,"given":"Pravesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-3565","authenticated-orcid":false,"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-8039","authenticated-orcid":false,"given":"Dharmveer","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-4096","authenticated-orcid":false,"given":"Ravindra","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Ambwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-1411","authenticated-orcid":false,"given":"Rimple Jeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcb.26174","volume":"119","author":"MSH Akash","year":"2018","unstructured":"Akash MSH, Rehman K, Liaqat A (2018) Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem 119:105\u2013110. https:\/\/doi.org\/10.1002\/jcb.26174","journal-title":"J Cell Biochem"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, Takagi H, Mizuno Y et al (2013a) Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 36:368\u2013373. https:\/\/doi.org\/10.1038\/hr.2012.196","journal-title":"Hypertens Res"},{"key":"1995_CR3","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/MCB.01340-06","volume":"27","author":"F Andreozzi","year":"2007","unstructured":"Andreozzi F, Laratta E, Procopio C et al (2007) Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 27:2372\u20132383. https:\/\/doi.org\/10.1128\/MCB.01340-06","journal-title":"Mol Cell Biol"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/IBPC.S6707","volume":"3","author":"J-P Baguet","year":"2010","unstructured":"Baguet J-P, Ormezzano O, Barone-Rochette G (2010) Impact of telmisartan in modifying vascular risk. Integr Blood Press Control 3:81\u201389","journal-title":"Integr Blood Press Control"},{"key":"1995_CR5","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","volume":"166","author":"P Balakumar","year":"2012","unstructured":"Balakumar P, Kathuria S (2012) Submaximal PPAR\u03b3 activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. Br J Pharmacol 166:1981\u20131992. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01938.x","journal-title":"Br J Pharmacol"},{"key":"1995_CR6","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran P, Hansen S, Waetzig GH et al (2018) The balance of interleukin (IL)-6, IL-6\u00b7soluble IL-6 receptor (sIL-6R), and IL-6\u00b7sIL-6R\u00b7sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem 293:6762\u20136775. https:\/\/doi.org\/10.1074\/jbc.RA117.001163","journal-title":"J Biol Chem"},{"key":"1995_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho CI et al (2004) Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3\u2013modulating activity. Hypertension 43:993\u20131002. https:\/\/doi.org\/10.1161\/01.HYP.0000123072.34629.57","journal-title":"Hypertension"},{"key":"1995_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103062","author":"N Bowker","year":"2020","unstructured":"Bowker N, Shah RL, Sharp SJ et al (2020) Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103062","journal-title":"EBioMedicine"},{"key":"1995_CR9","volume-title":"StatPearls","author":"KG Bulsara","year":"2024","unstructured":"Bulsara KG, Patel P, Cassagnol M (2024) Amlodipine. StatPearls. StatPearls Publishing, Treasure Island"},{"key":"1995_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107050","volume":"200","author":"E Caiazzo","year":"2024","unstructured":"Caiazzo E, Sharma M, Rezig AOM et al (2024) Circulating cytokines and risk of developing hypertension: a systematic review and meta-analysis. Pharmacol Res 200:107050. https:\/\/doi.org\/10.1016\/j.phrs.2023.107050","journal-title":"Pharmacol Res"},{"key":"1995_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00125-021-05380-z","volume":"64","author":"S-B Catrina","year":"2021","unstructured":"Catrina S-B, Zheng X (2021) Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 64:709\u2013716. https:\/\/doi.org\/10.1007\/s00125-021-05380-z","journal-title":"Diabetologia"},{"key":"1995_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1291\/hypres.30.1205","volume":"30","author":"D Chujo","year":"2007","unstructured":"Chujo D, Yagi K, Asano A et al (2007) Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 30:1205\u20131210. https:\/\/doi.org\/10.1291\/hypres.30.1205","journal-title":"Hypertens Res"},{"key":"1995_CR13","doi-asserted-by":"crossref","unstructured":"Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes | Diabetes | American Diabetes Association. https:\/\/diabetesjournals.org\/diabetes\/article\/52\/3\/812\/24000\/Inflammatory-Cytokines-and-the-Risk-to-Develop. Accessed 19 May 2025","DOI":"10.2337\/diabetes.52.3.812"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/ajh.2008.297","volume":"21","author":"C Delles","year":"2008","unstructured":"Delles C, Raff U, Mimran A et al (2008) Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 21:1330\u20131336. https:\/\/doi.org\/10.1038\/ajh.2008.297","journal-title":"Am J Hypertens"},{"key":"1995_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70155","volume":"13","author":"J Elford","year":"2025","unstructured":"Elford J, O\u2019Reilly RJ, Babey A-M et al (2025) Sulphonylureas as adjunct therapeutic agents in the treatment of autoimmune conditions: a narrative review. Pharmacol Res Perspect 13:e70155. https:\/\/doi.org\/10.1002\/prp2.70155","journal-title":"Pharmacol Res Perspect"},{"key":"1995_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113287","volume":"153","author":"D Felkle","year":"2022","unstructured":"Felkle D, Jarczy\u0144ski M, Kaleta K et al (2022) The immunomodulatory effects of antihypertensive therapy: a review. Biomed Pharmacother 153:113287. https:\/\/doi.org\/10.1016\/j.biopha.2022.113287","journal-title":"Biomed Pharmacother"},{"key":"1995_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/hr.2012.189","volume":"36","author":"A Fujimura","year":"2013","unstructured":"Fujimura A, Ushijima K, Ando H (2013) Does the PPAR-\u03b3-activating property of telmisartan provide a benefit in clinical practice? Hypertens Res 36:183\u2013183. https:\/\/doi.org\/10.1038\/hr.2012.189","journal-title":"Hypertens Res"},{"key":"1995_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/cmdc.200800285","volume":"4","author":"M Goebel","year":"2009","unstructured":"Goebel M, Clemenz M, Staels B et al (2009) Characterization of new PPAR\u03b3 agonists: analysis of Telmisartan\u2019s structural components. ChemMedChem 4:445\u2013456. https:\/\/doi.org\/10.1002\/cmdc.200800285","journal-title":"ChemMedChem"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.23736\/S0391-1977.18.02822-5","volume":"44","author":"Q He","year":"2019","unstructured":"He Q, Dong M, Pan Q et al (2019) Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 diabetes mellitus. Minerva Endocrinol 44:252\u2013258. https:\/\/doi.org\/10.23736\/S0391-1977.18.02822-5","journal-title":"Minerva Endocrinol"},{"key":"1995_CR20","doi-asserted-by":"publisher","first-page":"S513","DOI":"10.1161\/circ.118.suppl_18.S_513-b","volume":"118","author":"T Ichiki","year":"2008","unstructured":"Ichiki T, Tian Q, Imayama I, Sunagawa K (2008) Abstract 5249: telmisartan manifests powerful anti-inflammatory effects beyond class effects of angiotensin II type 1 blocker by inhibiting tumor necrosis factor \u03b1-induced interleukin 6 expressions through peroxisome proliferator activated receptor\u03b3 activation. Circulation 118:S513. https:\/\/doi.org\/10.1161\/circ.118.suppl_18.S_513-b","journal-title":"Circulation"},{"key":"1995_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cyto.2013.02.001","volume":"62","author":"L Klinghammer","year":"2013","unstructured":"Klinghammer L, Urschel K, Cicha I et al (2013) Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis\u2013influence on IP-10, TNF-\u03b1 and MCP-1. Cytokine 62:290\u2013296. https:\/\/doi.org\/10.1016\/j.cyto.2013.02.001","journal-title":"Cytokine"},{"key":"1995_CR22","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","volume":"54","author":"OP Kristiansen","year":"2005","unstructured":"Kristiansen OP, Mandrup-Poulsen T (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54:S114\u2013S124. https:\/\/doi.org\/10.2337\/diabetes.54.suppl_2.S114","journal-title":"Diabetes"},{"key":"1995_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816856","volume":"2015","author":"AJ Kroker","year":"2015","unstructured":"Kroker AJ, Bruning JB (2015) Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism. PPAR Res 2015:816856. https:\/\/doi.org\/10.1155\/2015\/816856","journal-title":"PPAR Res"},{"key":"1995_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","volume":"13","author":"E Lontchi-Yimagou","year":"2013","unstructured":"Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP (2013) Diabetes mellitus and inflammation. Curr Diab Rep 13:435\u2013444. https:\/\/doi.org\/10.1007\/s11892-013-0375-y","journal-title":"Curr Diab Rep"},{"key":"1995_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1515\/mr-2022-0002","volume":"2","author":"L Luo","year":"2022","unstructured":"Luo L, Liu M (2022) Adiponectin: friend or foe in obesity and inflammation. Med Rev 2:349\u2013362. https:\/\/doi.org\/10.1515\/mr-2022-0002","journal-title":"Med Rev"},{"key":"1995_CR26","doi-asserted-by":"publisher","first-page":"e22301","DOI":"10.7759\/cureus.22301","volume":"14","author":"BR Meher","year":"2022","unstructured":"Meher BR, Mohanty RR, Sahoo JP et al (2022) Comparative Study of the effects of Azilsartan and Telmisartan on insulin resistance and metabolic biomarkers in essential hypertension associated with type 2 diabetes mellitus. Cureus 14:e22301. https:\/\/doi.org\/10.7759\/cureus.22301","journal-title":"Cureus"},{"key":"1995_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/biomedicines10051168","volume":"10","author":"LV Nedosugova","year":"2022","unstructured":"Nedosugova LV, Markina YV, Bochkareva LA et al (2022) Inflammatory mechanisms of diabetes and its vascular complications. Biomedicines 10:1168. https:\/\/doi.org\/10.3390\/biomedicines10051168","journal-title":"Biomedicines"},{"key":"1995_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3317\/jraas.2006.045","volume":"7","author":"R Negro","year":"2006","unstructured":"Negro R, Hassan H (2006) The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin-Angiotensin-Aldosterone Syst 7:243\u2013246. https:\/\/doi.org\/10.3317\/jraas.2006.045","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"1995_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41440-018-0018-4","volume":"41","author":"S Nozato","year":"2018","unstructured":"Nozato S, Yamamoto K, Nozato Y et al (2018) Comparison between L-type and N\/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients. Hypertens Res 41:290\u2013298. https:\/\/doi.org\/10.1038\/s41440-018-0018-4","journal-title":"Hypertens Res"},{"key":"1995_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.HYP.0000113044.46326.98","volume":"43","author":"JM Orshal","year":"2004","unstructured":"Orshal JM, Khalil RA (2004) Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 43:434\u2013444. https:\/\/doi.org\/10.1161\/01.HYP.0000113044.46326.98","journal-title":"Hypertension"},{"key":"1995_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2018.00001","volume":"5","author":"N Pechlivani","year":"2018","unstructured":"Pechlivani N, Ajjan RA (2018) Thrombosis and vascular inflammation in diabetes: mechanisms and potential therapeutic targets. Front Cardiovasc Med 5:1. https:\/\/doi.org\/10.3389\/fcvm.2018.00001","journal-title":"Front Cardiovasc Med"},{"key":"1995_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1161\/HYPERTENSIONAHA.123.22714","volume":"81","author":"TB Plante","year":"2024","unstructured":"Plante TB, Juraschek SP, Howard G et al (2024) Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension 81:1244\u20131253. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.22714","journal-title":"Hypertension"},{"key":"1995_CR33","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/bph.12713","volume":"171","author":"D Qu","year":"2014","unstructured":"Qu D, Liu J, Lau CW, Huang Y (2014) IL-6 in diabetes and cardiovascular complications. Br J Pharmacol 171:3595\u20133603. https:\/\/doi.org\/10.1111\/bph.12713","journal-title":"Br J Pharmacol"},{"key":"1995_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00129784-200606040-00003","volume":"6","author":"R R\u00edos-V\u00e1zquez","year":"2006","unstructured":"R\u00edos-V\u00e1zquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC (2006) Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs Drugs Devices Interv 6:231\u2013242. https:\/\/doi.org\/10.2165\/00129784-200606040-00003","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"1995_CR35","doi-asserted-by":"publisher","DOI":"10.4236\/ojemd.2013.33026","author":"RM Salama","year":"2013","unstructured":"Salama RM, Schaalan MF, Ibrahim ME et al (2013) Effectiveness of Telmisartan as an adjunct to metformin in treating type II diabetes mellitus in rats. Open J Endocrine Metab Dis. https:\/\/doi.org\/10.4236\/ojemd.2013.33026","journal-title":"Open J Endocrine Metab Dis"},{"key":"1995_CR36","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/ijms20143458","volume":"20","author":"IVG Silva","year":"2019","unstructured":"Silva IVG, de Figueiredo RC, Rios DRA (2019) Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci 20:3458. https:\/\/doi.org\/10.3390\/ijms20143458","journal-title":"Int J Mol Sci"},{"key":"1995_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11906-015-0601-x","volume":"17","author":"M Stump","year":"2015","unstructured":"Stump M, Mukohda M, Hu C, Sigmund CD (2015) Ppar\u03b3 regulation in hypertension and metabolic syndrome. Curr Hypertens Rep 17:89. https:\/\/doi.org\/10.1007\/s11906-015-0601-x","journal-title":"Curr Hypertens Rep"},{"key":"1995_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijcard.2012.01.104","volume":"156","author":"H Takagi","year":"2012","unstructured":"Takagi H, Yamamoto H, Iwata K et al (2012) Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials. Int J Cardiol 156:238\u2013241. https:\/\/doi.org\/10.1016\/j.ijcard.2012.01.104","journal-title":"Int J Cardiol"},{"key":"1995_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"Takagi H, Mizuno Y, Yamamoto H et al (2013) Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 36:368\u2013373. https:\/\/doi.org\/10.1038\/hr.2012.196","journal-title":"Hypertens Res"},{"key":"1995_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1755-5922.2009.00079.x","volume":"27","author":"A Takahara","year":"2009","unstructured":"Takahara A (2009) Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 27:124\u2013139. https:\/\/doi.org\/10.1111\/j.1755-5922.2009.00079.x","journal-title":"Cardiovasc Ther"},{"key":"1995_CR41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/HYPERTENSIONAHA.108.126656","volume":"53","author":"Q Tian","year":"2009","unstructured":"Tian Q, Miyazaki R, Ichiki T et al (2009) Inhibition of tumor necrosis factor-\u03b1\u2013induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-\u03b3 with nuclear factor \u03baB and CCAAT\/enhancer-binding protein-\u03b2. Hypertension 53:798\u2013804. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.126656","journal-title":"Hypertension"},{"key":"1995_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41440-018-0014-8","volume":"41","author":"S Toyoda","year":"2018","unstructured":"Toyoda S, Sakuma M, Node K, Inoue T (2018) Pleiotropic effects of calcium channel blockers. Hypertens Res 41:230\u2013233. https:\/\/doi.org\/10.1038\/s41440-018-0014-8","journal-title":"Hypertens Res"},{"key":"1995_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","volume":"14","author":"S Tsalamandris","year":"2019","unstructured":"Tsalamandris S, Antonopoulos AS, Oikonomou E et al (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol Rev 14:50\u201359. https:\/\/doi.org\/10.15420\/ecr.2018.33.1","journal-title":"Eur Cardiol Rev"},{"key":"1995_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s0014-5793(01)03109-x","volume":"508","author":"Z Wang","year":"2001","unstructured":"Wang Z, Castresana MR, Newman WH (2001) NF-kappaB is required for TNF-alpha-directed smooth muscle cell migration. FEBS Lett 508:360\u2013364. https:\/\/doi.org\/10.1016\/s0014-5793(01)03109-x","journal-title":"FEBS Lett"},{"key":"1995_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/dc12-0702","volume":"36","author":"X Wang","year":"2013","unstructured":"Wang X, Bao W, Liu J et al (2013) Inflammatory markers and risk of type 2 diabetes. Diabetes Care 36:166\u2013175. https:\/\/doi.org\/10.2337\/dc12-0702","journal-title":"Diabetes Care"},{"key":"1995_CR46","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.metabol.2013.01.019","volume":"62","author":"TW Weiss","year":"2013","unstructured":"Weiss TW, Arnesen H, Seljeflot I (2013) Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism 62:1008\u20131013. https:\/\/doi.org\/10.1016\/j.metabol.2013.01.019","journal-title":"Metabolism"},{"key":"1995_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jphs.2018.11.007","volume":"139","author":"J Wen","year":"2019","unstructured":"Wen J, Zeng M, Liu Z et al (2019) The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. J Pharmacol Sci 139:37\u201341. https:\/\/doi.org\/10.1016\/j.jphs.2018.11.007","journal-title":"J Pharmacol Sci"},{"key":"1995_CR48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00228-023-03541-0","volume":"79","author":"D Xie","year":"2023","unstructured":"Xie D, Wang Q, Huang W, Zhao L (2023) Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes. Eur J Clin Pharmacol 79:1291\u20131301. https:\/\/doi.org\/10.1007\/s00228-023-03541-0","journal-title":"Eur J Clin Pharmacol"},{"key":"1995_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084186","volume":"25","author":"K Yamagata","year":"2024","unstructured":"Yamagata K, Tsuyama T, Sato Y (2024) Roles of \u03b2-cell hypoxia in the progression of type 2 diabetes. Int J Mol Sci 25:4186. https:\/\/doi.org\/10.3390\/ijms25084186","journal-title":"Int J Mol Sci"},{"key":"1995_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1253\/circj.cj-13-0741","volume":"78","author":"K Yamaguchi","year":"2014","unstructured":"Yamaguchi K, Wakatsuki T, Soeki T et al (2014) Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients. Circ J 78:240\u2013247. https:\/\/doi.org\/10.1253\/circj.cj-13-0741","journal-title":"Circ J"},{"key":"1995_CR51","first-page":"3327","volume":"12","author":"Y Yan","year":"2017","unstructured":"Yan Y, Liu W (2017) Effect of metformin combined with telmisartan on blood pressure and insulin in obese hypertensive patients with impaired glucose tolerance. Chin J Prim Med Pharm 12:3327\u20133331","journal-title":"Chin J Prim Med Pharm"},{"key":"1995_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/cvr\/cvq392","volume":"90","author":"CY Yuen","year":"2011","unstructured":"Yuen CY, Wong WT, Tian XY et al (2011) Telmisartan inhibits vasoconstriction via PPAR\u03b3-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 90:122\u2013129. https:\/\/doi.org\/10.1093\/cvr\/cvq392","journal-title":"Cardiovasc Res"},{"key":"1995_CR53","doi-asserted-by":"publisher","first-page":"11756","DOI":"10.1021\/acsomega.1c01170","volume":"6","author":"X Zhang","year":"2021","unstructured":"Zhang X, Dong Y, Dong H et al (2021) Telmisartan mitigates TNF-\u03b1-induced type II collagen reduction by upregulating SOX-9. ACS Omega 6:11756\u201311761. https:\/\/doi.org\/10.1021\/acsomega.1c01170","journal-title":"ACS Omega"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01995-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:03:52Z","timestamp":1763420632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01995-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01995-5","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,5]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of AIIMS, Jodhpur (AIIMS\/IEC\/2023\/56\/3) on 18\/03\/2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}